Objective To observe the efficacy of modified Tongqi San and Erchen Decoction on secretory otitis media and its impact on interleukin (IL)/soluble suppression of tumorigenicity 2 (sST2) signalingpathway.
Methods A total of 90 patients with secretory otitis media were selected as study objects, and were divided into observation group and control group according to random number table method, with 45 cases in each group. The control group was given routine comprehensive treatment, and the observation group was given modified Tongqi San and Erchen Decoction on the basis of the control group. The efficacy and adverse reactions were observed in the two groups after treatment, and the pure tone hearing threshold, Chinese Version of Chronic Ear Survey (CCES), IL-33, sST2, nuclear factor-κB (NF-κB), IL-5, interferon (INF)-γ, and IL-13 levels were also compared in two groups before and after treatment.
Results The total effective rate in the observation group was 91.11%, which was significantly better than 73.33% in the control group (P < 0.05). The incidence of adverse reactions after treatment showed no statistically significant difference between the two groups (P>0.05). After treatment, the pure tone hearing threshold and CCES score in two groups were significantly higher than before treatment, and the IL-33, sST2, NF-κB, IL-5, INF-γ and IL-13 levels in two groups were significantly decreased than before treatment (P < 0.01). The pure tone hearing threshold and CCES score were higher than those of the control group, and the levels of IL-33, SST2, NF-κB, IL-5, INF-γ and IL-13 in the observation group were lower than those in the control group, and the difference was statistically significant (P < 0.01).
Conclusion Modified Tongqi San and Erchen Decoction has obvious efficacy on secretory otitis media, and it can promote hearing recovery and reduce the release of inflammatory mediators in the body, which may be related to the regulation of IL-33/sST2 signaling pathway.
DownLoad: